TABLE 4.
Demographic, biochemical and clinical characteristics of nephrosclerosis patients with or without cardiovascular events (CVE) recorded during the four-year follow-up.
| No CVE | CVE | p | |
|---|---|---|---|
| Patients | 452 | 41 | |
| Men | 300 (66.4%) | 34 (82.9%) | 0.02 |
| Women | 152 (33.-6%) | 7 (17.1%) | |
| Age (years) | 66 (24–89) | 67 (53–78) | 0.01 |
| Weight (kg) | 79.8 (38–135) | 81.4 (52–125) | 0.56 |
| Body mass index | 29.4 (18.71–51.73) | 29.7 (20.31–48.83) | 0.55 |
| Waist circumference (cm) | 100 (67–138) | 104 (69–131) | 0.36 |
| Tobacco | |||
| Nonsmokers | 190 (42%) | 13 (31.7%) | 0.22 |
| Former smokers | 185 (40.9%) | 17 (41.5%) | |
| Current smokers | 77 (17%) | 11 (26.8%) | |
| Hypertension | 435 (96.2%) | 39 (95.1%) | 0.72 |
| Diabetes Mellitus | 100 (22.1%) | 14 (34.1%) | 0.08 |
| Dyslipidemia | 284 (67.8%) | 30 (73.2%) | 0.47 |
| Chronic kidney disease | |||
| Stage 5D | 57 (12.6%) | 6 (14.6%) | 0.93 |
| Stage 4–5 | 113 (25%) | 10 (24.4%) | |
| Stage 3 | 282 (62.4%) | 25 (60.9%) | |
| Biochemical findings | |||
| Cholesterol (mg/dl) | 181 (76–317) | 165 (108–317) | 0.06 |
| Glucose (mg/dl) | 100.5 (47–355) | 102 (56–195) | 0.13 |
| eGFR (MDRD4) | 38.2 (5–60.74) | 37.4 (13–59.6) | 0.7 |
| Albumin/Cr (mg/g) | 68.9 (0.01–4,391.65) | 173.6 (0.21–4,583.89) | 0.17 |